Evoke Pharma Inc EVOK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EVOK is a good fit for your portfolio.
News
-
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
-
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
-
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
-
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
-
Evoke Pharma Announces Closing of $7.5 Million Public Offering
-
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
Trading Information
- Previous Close Price
- $0.44
- Day Range
- $0.44–0.48
- 52-Week Range
- $0.42–2.40
- Bid/Ask
- $0.44 / $0.48
- Market Cap
- $3.88 Mil
- Volume/Avg
- 8,742 / 41,967
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.29
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 4
- Website
- https://www.evokepharma.com
Valuation
|
Metric
|
EVOK
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.29 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EVOK
|
|---|---|
Quick Ratio | 1.78 |
Current Ratio | 2.25 |
Interest Coverage | −14.86 |
Quick Ratio
EVOK
Profitability
|
Metric
|
EVOK
|
|---|---|
Return on Assets (Normalized) | −72.77% |
Return on Equity (Normalized) | −1,010.99% |
Return on Invested Capital (Normalized) | −110.26% |
Return on Assets
EVOK
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Vwvjpmfmpt | Hrtgvpr | $69.8 Bil | |
ZTS
| Zoetis Inc Class A | Ykdsqpxpz | Nwsys | $68.9 Bil | |
HLN
| Haleon PLC ADR | Gctbkxwp | Ksdv | $37.7 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Xggwxmlgq | Hsdw | $14.8 Bil | |
VTRS
| Viatris Inc | Prmcntd | Blv | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Slbxfqgv | Xfsd | $11.9 Bil | |
CTLT
| Catalent Inc | Vqlqzkhh | Tnyykm | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Nlhvlsy | Hcj | $4.2 Bil | |
CURLF
| Curaleaf Holdings Inc | Csclcsml | Rxbdv | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Jljlcvgr | Xjqzfw | $3.5 Bil |